Eisai Secures UK Grant to Expand Hatfield Manufacturing Site
Manufacturing Intelligence — June 17, 2026
What to Watch
- UK co-investment momentum for biologics infrastructure: Eisai’s £48M Hatfield cold-chain grant tests whether the UK can convert one-off project support into a sustained inbound investment thesis comparable to Ireland’s tax-and-incentive package. Watch for follow-on UK government announcements supporting biologics fill-finish or cold-chain projects from other multinationals, which would signal a coordinated industrial policy rather than an isolated deal.
- Bispecific antibody CDMO capacity race: With PharmaSource’s 2026 market guide confirming a structural capacity gap in bispecific antibody manufacturing, track capacity announcements from WuXi Biologics, Samsung Biologics, Lonza, and emerging specialists over Q3 2026. The first CDMO to credibly offer end-to-end bispecific manufacturing with integrated analytical development at commercial scale will capture disproportionate share of a rapidly growing contract manufacturing segment.
- Cellares commercial-scale ramp ahead of 2027 capacity target: With Series D extended to $327M, Cellares’ 2026–27 buildout in South San Francisco, Bridgewater, Leiden, and Kashiwa City is now well capitalized. Watch for execution milestones — first GMP runs on the Cell Shuttle platform and any new customer announcements beyond BMS and Cabaletta — as leading indicators of whether the automated CGT manufacturing thesis converts to demand at commercial scale.
This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.
